CA2978736C - Dosing regimen of tradipitant - Google Patents
Dosing regimen of tradipitant Download PDFInfo
- Publication number
- CA2978736C CA2978736C CA2978736A CA2978736A CA2978736C CA 2978736 C CA2978736 C CA 2978736C CA 2978736 A CA2978736 A CA 2978736A CA 2978736 A CA2978736 A CA 2978736A CA 2978736 C CA2978736 C CA 2978736C
- Authority
- CA
- Canada
- Prior art keywords
- tradipitant
- dose
- disease
- day
- disorder ameliorated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Encapsulation Of And Coatings For Semiconductor Or Solid State Devices (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Eye Examination Apparatus (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA3213864A CA3213864C (en) | 2015-03-04 | 2016-03-04 | Dosing regimen of tradipitant |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562128472P | 2015-03-04 | 2015-03-04 | |
| US62/128,472 | 2015-03-04 | ||
| US201562232644P | 2015-09-25 | 2015-09-25 | |
| US62/232,644 | 2015-09-25 | ||
| PCT/US2016/021015 WO2016141341A1 (en) | 2015-03-04 | 2016-03-04 | Method of treatment with tradipitant |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3213864A Division CA3213864C (en) | 2015-03-04 | 2016-03-04 | Dosing regimen of tradipitant |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2978736A1 CA2978736A1 (en) | 2016-09-09 |
| CA2978736C true CA2978736C (en) | 2023-11-07 |
Family
ID=55629110
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2978736A Active CA2978736C (en) | 2015-03-04 | 2016-03-04 | Dosing regimen of tradipitant |
Country Status (19)
| Country | Link |
|---|---|
| US (6) | US10463655B2 (enExample) |
| EP (2) | EP3265087B1 (enExample) |
| JP (4) | JP6891385B2 (enExample) |
| KR (3) | KR20170122777A (enExample) |
| CN (2) | CN113262221A (enExample) |
| AU (4) | AU2016226006B2 (enExample) |
| BR (1) | BR112017018620A2 (enExample) |
| CA (1) | CA2978736C (enExample) |
| CL (1) | CL2017002238A1 (enExample) |
| DK (1) | DK3265087T3 (enExample) |
| ES (1) | ES2824552T3 (enExample) |
| HR (1) | HRP20201627T1 (enExample) |
| HU (1) | HUE050944T2 (enExample) |
| IL (1) | IL254142B (enExample) |
| MX (2) | MX385788B (enExample) |
| PT (1) | PT3265087T (enExample) |
| RU (1) | RU2770050C2 (enExample) |
| WO (1) | WO2016141341A1 (enExample) |
| ZA (1) | ZA201706059B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112017018620A2 (pt) * | 2015-03-04 | 2018-04-17 | Vanda Pharmaceuticals Inc. | método de administração de tradipitanto, e, tradipitanto. |
| KR20200054232A (ko) * | 2017-09-13 | 2020-05-19 | 반다 파마슈티칼즈, 인코퍼레이티드. | 트라디피탄트를 이용한 아토피 피부염의 개선된 치료 |
| IL274541B2 (en) * | 2017-11-17 | 2024-10-01 | Vanda Pharmaceuticals Inc | Method of treatment of gastrointestinal diseases with tradipitant |
| EP3801514A1 (en) | 2018-06-08 | 2021-04-14 | Vanda Pharmaceuticals Inc. | Method of treatment with tradipitant |
| US10821099B2 (en) | 2018-09-28 | 2020-11-03 | Vanda Pharmaceuticals Inc. | Use of tradipitant in motion sickness |
| EP4450126A3 (en) * | 2018-09-28 | 2025-02-19 | Vanda Pharmaceuticals Inc. | Use of tradipitant in motion sickness |
| WO2020117811A1 (en) | 2018-12-03 | 2020-06-11 | Vanda Pharmaceuticals Inc. | Method of treatment with tradipitant |
| WO2020132513A1 (en) | 2018-12-21 | 2020-06-25 | Vanda Pharmaceuticals Inc. | Improved treatment of atopic dermatitis with tradipitant |
| JP2023515167A (ja) * | 2020-02-25 | 2023-04-12 | バンダ・ファーマシューティカルズ・インコーポレイテッド | トラジピタントによるアトピー性皮膚炎の改善された治療 |
| US20230145932A1 (en) * | 2020-03-26 | 2023-05-11 | Vanda Pharmaceuticals Inc. | Treatment of lower respiratory tract infection with tradipitant |
| WO2023019084A1 (en) | 2021-08-12 | 2023-02-16 | Vanda Pharmaceuticals Inc. | Treatment of gastric accommodation with tradipitant |
| US20240350469A1 (en) | 2021-08-31 | 2024-10-24 | Vanda Pharmaceuticals Inc. | Treatment of lower respiratory tract infection with tradipitant |
| EP4637766A1 (en) | 2022-12-21 | 2025-10-29 | Vanda Pharmaceuticals Inc. | Methods of treatment with tradipitant |
| EP4599831A1 (en) | 2024-02-09 | 2025-08-13 | Vanda Pharmaceuticals Inc. | Treatment of gastroparesis with tradipitant |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9305718D0 (en) | 1993-03-19 | 1993-05-05 | Glaxo Group Ltd | Medicaments |
| TW263498B (enExample) * | 1993-11-10 | 1995-11-21 | Takeda Pharm Industry Co Ltd | |
| GB9513972D0 (en) | 1995-07-08 | 1995-09-06 | Merck Sharp & Dohme | Pharmaceutical compositions |
| ES2359235T3 (es) | 1999-02-24 | 2011-05-19 | F. Hoffmann-La Roche Ag | Derivados de 4-fenilpiridina y su empleo como antagonistas del receptor nk-1. |
| US6849624B2 (en) * | 2001-07-31 | 2005-02-01 | Hoffmann-La Roche Inc. | Aromatic and heteroaromatic substituted amides |
| EA007720B1 (ru) * | 2002-04-26 | 2006-12-29 | Эли Лилли Энд Компани | Производные триазола в качестве антагонистов рецептора тахикинина |
| ES2307925T3 (es) * | 2002-04-26 | 2008-12-01 | Eli Lilly And Company | Antagonistas de los receptores de la taquiquinina. |
| JP2004250329A (ja) | 2002-12-26 | 2004-09-09 | Dainippon Pharmaceut Co Ltd | イサチン誘導体 |
| US7135575B2 (en) * | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| DE602004026333D1 (de) * | 2003-10-24 | 2010-05-12 | Lilly Co Eli | NEUE KRISTALLINE FORMEN VON ä2-Ä1-(3,5-BISTRIFLUORMETHYLBENZYL)-5-PYRIDIN-4-YL-1H-Ä1,2,3ÜÜTRIAZOL-4-YLÜ-PYRIDIN-3-YLü-(2-CHLORPHENYL)METHANON |
| JP4673068B2 (ja) | 2005-01-19 | 2011-04-20 | 独立行政法人科学技術振興機構 | Ｔｈ１型アレルギー疾患治療用組成物 |
| DE102005006217B4 (de) | 2005-02-07 | 2007-08-16 | Universitätsklinikum Hamburg-Eppendorf | Diagnose von allergischen Erkrankungen und/oder atopischen Erkrankungen durch Nachweis von Autoantikörpern gegen CD28 in humanem Serum |
| US20090264388A1 (en) | 2006-02-22 | 2009-10-22 | Valorisation Recherche Hscm, Limited Partnership | Compounds and Methods of Treating Disorders Associated With Activation of Metachromatic Cells |
| HRP20140613T1 (hr) | 2006-12-20 | 2014-08-15 | Eli Lilly And Company | Novi intermedijer i postupak koji je koristan za dobivanje {2-[1-(3,5-bi-trifluorometil-benzil)-5-piridin-4-il-1h-[1,2,3]triazol-4-il]-piridin-3-il}-(2-klorofenil)-metanona |
| CN105503870A (zh) | 2009-08-14 | 2016-04-20 | 欧科生医股份有限公司 | 神经激肽-1拮抗剂的静脉内制剂 |
| EP2722045B1 (en) | 2009-11-18 | 2016-07-06 | Helsinn Healthcare SA | Compositions for treating centrally mediated nausea and vomiting |
| MX2012005347A (es) | 2009-11-18 | 2012-08-03 | Helsinn Healthcare Sa | Composiciones para tratar nausea y vomito centralmente mediados. |
| US20150320866A1 (en) | 2012-12-13 | 2015-11-12 | Heron Therapeutics, Inc. | Pharmaceutical composition comprising antiemetic compounds and polyorthoester |
| JP6644328B2 (ja) | 2013-02-28 | 2020-02-12 | ロート製薬株式会社 | アトピー性疾患の発症又は重症化リスクの評価法 |
| WO2014209962A1 (en) * | 2013-06-24 | 2014-12-31 | Tigercat Pharma, Inc. | Use of nk-1 receptor antagonist serlopitant in pruritus |
| US8906951B1 (en) * | 2013-06-24 | 2014-12-09 | Tigercat Pharma, Inc. | Use of NK-1 receptor antagonists in pruritus |
| BR112017018620A2 (pt) * | 2015-03-04 | 2018-04-17 | Vanda Pharmaceuticals Inc. | método de administração de tradipitanto, e, tradipitanto. |
| WO2016195723A1 (en) | 2015-06-03 | 2016-12-08 | Beller Pharmaceuticals LLC | Methods of treatment for conditions mediated by substance p |
| WO2017060488A1 (en) | 2015-10-09 | 2017-04-13 | Almirall, S.A. | New trpa1 antagonists |
| PL3383363T3 (pl) | 2015-11-30 | 2021-05-31 | Anacor Pharmaceuticals, Inc. | Preparaty farmaceutyczne do stosowania miejscowego do leczenia stanów związanych z zapaleniem |
| US11324832B2 (en) | 2015-12-22 | 2022-05-10 | Endosome Therapeutics, Inc. | Tripartite modulators of endosomal G protein-coupled receptors |
| KR20200054232A (ko) * | 2017-09-13 | 2020-05-19 | 반다 파마슈티칼즈, 인코퍼레이티드. | 트라디피탄트를 이용한 아토피 피부염의 개선된 치료 |
| IL274541B2 (en) * | 2017-11-17 | 2024-10-01 | Vanda Pharmaceuticals Inc | Method of treatment of gastrointestinal diseases with tradipitant |
| EP3801514A1 (en) * | 2018-06-08 | 2021-04-14 | Vanda Pharmaceuticals Inc. | Method of treatment with tradipitant |
| US10821099B2 (en) | 2018-09-28 | 2020-11-03 | Vanda Pharmaceuticals Inc. | Use of tradipitant in motion sickness |
| EP4450126A3 (en) * | 2018-09-28 | 2025-02-19 | Vanda Pharmaceuticals Inc. | Use of tradipitant in motion sickness |
| WO2020117811A1 (en) * | 2018-12-03 | 2020-06-11 | Vanda Pharmaceuticals Inc. | Method of treatment with tradipitant |
-
2016
- 2016-03-04 BR BR112017018620-9A patent/BR112017018620A2/pt not_active Application Discontinuation
- 2016-03-04 CA CA2978736A patent/CA2978736C/en active Active
- 2016-03-04 KR KR1020177026588A patent/KR20170122777A/ko not_active Ceased
- 2016-03-04 CN CN202110527432.8A patent/CN113262221A/zh active Pending
- 2016-03-04 HR HRP20201627TT patent/HRP20201627T1/hr unknown
- 2016-03-04 MX MX2017011279A patent/MX385788B/es unknown
- 2016-03-04 JP JP2017546704A patent/JP6891385B2/ja active Active
- 2016-03-04 CN CN201680013797.6A patent/CN107427502B/zh active Active
- 2016-03-04 KR KR1020237043041A patent/KR102860817B1/ko active Active
- 2016-03-04 KR KR1020257030197A patent/KR20250136946A/ko active Pending
- 2016-03-04 HU HUE16711931A patent/HUE050944T2/hu unknown
- 2016-03-04 EP EP16711931.2A patent/EP3265087B1/en active Active
- 2016-03-04 EP EP20180523.1A patent/EP3730140A1/en active Pending
- 2016-03-04 US US15/553,394 patent/US10463655B2/en active Active
- 2016-03-04 ES ES16711931T patent/ES2824552T3/es active Active
- 2016-03-04 PT PT167119312T patent/PT3265087T/pt unknown
- 2016-03-04 AU AU2016226006A patent/AU2016226006B2/en active Active
- 2016-03-04 DK DK16711931.2T patent/DK3265087T3/da active
- 2016-03-04 WO PCT/US2016/021015 patent/WO2016141341A1/en not_active Ceased
- 2016-03-04 RU RU2017134443A patent/RU2770050C2/ru active
-
2017
- 2017-08-24 IL IL254142A patent/IL254142B/en unknown
- 2017-09-04 MX MX2021010460A patent/MX2021010460A/es unknown
- 2017-09-04 CL CL2017002238A patent/CL2017002238A1/es unknown
- 2017-09-06 ZA ZA2017/06059A patent/ZA201706059B/en unknown
-
2019
- 2019-06-04 US US16/430,514 patent/US10772880B2/en active Active
- 2019-06-04 US US16/430,516 patent/US20190290626A1/en not_active Abandoned
-
2020
- 2020-07-31 US US16/944,596 patent/US11324735B2/en active Active
-
2021
- 2021-01-28 JP JP2021012356A patent/JP2021073258A/ja active Pending
- 2021-05-10 AU AU2021202956A patent/AU2021202956B2/en active Active
-
2022
- 2022-04-06 US US17/714,998 patent/US12318375B2/en active Active
-
2023
- 2023-01-18 JP JP2023006082A patent/JP2023052486A/ja active Pending
- 2023-09-21 AU AU2023233141A patent/AU2023233141B2/en active Active
-
2024
- 2024-04-09 JP JP2024062811A patent/JP2024074963A/ja not_active Withdrawn
-
2025
- 2025-03-12 US US19/078,214 patent/US20250205213A1/en active Pending
- 2025-08-04 AU AU2025210905A patent/AU2025210905A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2978736C (en) | Dosing regimen of tradipitant | |
| AU2017315781B2 (en) | Use of pridopidine for treating dystonias | |
| CN106999467A (zh) | 治疗认知减退的方法 | |
| JP6145946B2 (ja) | 併用ａｌｓ療法 | |
| JP2013501805A (ja) | 脱髄性および他の神経系疾患を患っている患者における神経認知的および／または神経精神医学的障害を改善するための４−アミノピリジンの使用 | |
| KR20160118234A (ko) | 만성 신장병의 진행 억제 또는 개선제 | |
| CA3213864C (en) | Dosing regimen of tradipitant | |
| RU2810253C2 (ru) | Способ лечения с применением традипитанта | |
| HK1248552B (en) | Method of treatment with tradipitant | |
| CN112789044A (zh) | 使用ccr3-抑制剂治疗衰老相关损伤的方法及组合物 | |
| Al-Ghani et al. | Estimation of Catha edulis (Vahl) Forssk. ex Endl.-antidiabetic drug interactions by using closed-loop Doluisio’s method | |
| HK40019123A (en) | Methods and compositions for treating aging-associated impairments using ccr3-inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20210218 |
|
| EEER | Examination request |
Effective date: 20210218 |
|
| EEER | Examination request |
Effective date: 20210218 |
|
| EEER | Examination request |
Effective date: 20210218 |
|
| EEER | Examination request |
Effective date: 20210218 |
|
| EEER | Examination request |
Effective date: 20210218 |
|
| EEER | Examination request |
Effective date: 20210218 |
|
| EEER | Examination request |
Effective date: 20210218 |
|
| EEER | Examination request |
Effective date: 20210218 |